H1N1感染症(H1N1 Infection)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
H1N1 Infection Overview 8
Therapeutics Development 9
Pipeline Products for H1N1 Infection – Overview 9
Pipeline Products for H1N1 Infection – Comparative Analysis 10
H1N1 Infection – Therapeutics under Development by Companies 11
H1N1 Infection – Therapeutics under Investigation by Universities/Institutes 15
H1N1 Infection – Pipeline Products Glance 17
Clinical Stage Products 17
Early Stage Products 18
H1N1 Infection – Products under Development by Companies 19
H1N1 Infection – Products under Investigation by Universities/Institutes 22
H1N1 Infection – Companies Involved in Therapeutics Development 23
Adamas Pharmaceuticals, Inc. 23
Akshaya Bio Inc. 24
AlphaVax, Inc. 25
Antigen Express, Inc. 26
Beijing Minhai Biotechnology Co., Ltd 27
Bionor Pharma ASA 28
CEL-SCI Corporation 29
Cilian AG 30
Colby Pharmaceutical Company 31
Crucell N.V. 32
EpiVax, Inc. 33
Etubics Corporation 34
Gemmus Pharma Inc. 35
iBio, Inc. 36
Inovio Pharmaceuticals, Inc. 37
Johnson & Johnson 38
Kineta, Inc. 39
Kyowa Hakko Kirin Co., Ltd. 40
Medicago Inc. 41
NanoViricides, Inc. 42
Onxeo SA 43
OPKO Health, Inc. 44
REPLICor Inc. 45
Revivicor, Inc. 46
Sarepta Therapeutics, Inc. 47
Sirnaomics, Inc. 48
TaiMed Biologics Inc. 49
Takeda Pharmaceutical Company Limited 50
TechnoVax, Inc. 51
Vaxart, Inc. 52
Vaxin, Inc. 53
Vaxine Pty Ltd 54
H1N1 Infection – Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Combination Products 56
Assessment by Target 57
Assessment by Mechanism of Action 59
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
ADS-324 – Drug Profile 65
AEA-35p – Drug Profile 66
Antisense RNAi Oligonucleotides to Inhibit Matriptase for Influenza – Drug Profile 67
Aspidasept – Drug Profile 68
BA-032 – Drug Profile 69
C-05 – Drug Profile 70
CiFlu – Drug Profile 71
CR-9114 – Drug Profile 73
CYM-5442 – Drug Profile 74
diridavumab – Drug Profile 75
FVH-1 – Drug Profile 77
Gamma-Flu – Drug Profile 78
GP-1001 – Drug Profile 79
GP-1681 – Drug Profile 80
GREFLU/CAL – Drug Profile 82
H1N1 [A/Aichi/2/68] vaccine – Drug Profile 83
Human Antibody Based Vaccines – Drug Profile 84
Influ-nRNA – Drug Profile 86
influenza (strain H5N1, H1N1) vaccine – Drug Profile 87
influenza [H1N1] (quadrivalent) virus like particle vaccine – Drug Profile 88
influenza [H1N1] vaccine – Drug Profile 90
influenza [strain A/H1N1] vaccine – Drug Profile 91
influenza [strain H1N1] (mutivalent) vaccine – Drug Profile 92
influenza [strain H1N1] vaccine – Drug Profile 93
influenza A vaccine – Drug Profile 94
influenza vaccine – Drug Profile 95
influenza vaccine – Drug Profile 96
influenza vaccine – Drug Profile 98
influenza vaccine [H1N1] – Drug Profile 99
Innate Immune Agonists – Drug Profile 101
INO-3401 – Drug Profile 102
INO-3510 – Drug Profile 103
INO-3605 – Drug Profile 104
INO-3609 – Drug Profile 105
JVRS-100 + influenza [H1N1/H3N2] vaccine – Drug Profile 106
LEAPS-H1N1-DC – Drug Profile 107
NVINF-1 – Drug Profile 108
NVINF-2 – Drug Profile 110
pandemic influenza [H1N1] (monovalent) vaccine – Drug Profile 111
pandemic influenza [H5N1/H1N1] vaccine – Drug Profile 112
pandemic influenza vaccine [H1N1] – Drug Profile 113
radavirsen – Drug Profile 114
REP-9 – Drug Profile 116
RNAi Oligonucleotides to Inhibit Matriptase for H1N1 Infection – Drug Profile 117
Small Molecules to Block M2 Channel for Influenza Infections – Drug Profile 118
STP-702 – Drug Profile 119
Synthetic Peptides for Influenza, HSV and HIV Infections – Drug Profile 120
TMB-571 – Drug Profile 121
TVX-002 – Drug Profile 122
Vacc-Flu – Drug Profile 123
Vaccine to Target TLR2 for Infectious Disease – Drug Profile 124
VH-244 – Drug Profile 125
VX-787 – Drug Profile 127
VXAA-1.1 – Drug Profile 128
Z-3G1 – Drug Profile 129
H1N1 Infection – Recent Pipeline Updates 130
H1N1 Infection – Dormant Projects 143
H1N1 Infection – Product Development Milestones 146
Featured News & Press Releases 146
Appendix 156
Methodology 156
Coverage 156
Secondary Research 156
Primary Research 156
Expert Panel Validation 156
Contact Us 156
Disclaimer 157